A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m(−2), administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeung, H-C, Rha, S Y, Cho, B C, Yoo, N C, Roh, J K, Roh, W J, Chung, H C, Ahn, J B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360769/
https://www.ncbi.nlm.nih.gov/pubmed/17106441
http://dx.doi.org/10.1038/sj.bjc.6603468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360769/
https://www.ncbi.nlm.nih.gov/pubmed/17106441
http://dx.doi.org/10.1038/sj.bjc.6603468

Ejemplares similares